Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Biomarkers associated with Alzheimer’s disease (AD)-like brain atrophy in healthy people may identify mechanisms involved in early stage AD. Aside from cerebrospinal fluid (CSF) β-amyloid42 (Aβ42) and tau, no studies have tested associations between CSF proteins and AD-like brain atrophy. We studied 90 healthy elders, who underwent lumbar puncture at baseline, and serial magnetic resonance imaging scans for up to 4 years. We tested statistical effects of baseline CSF proteins (N=70 proteins related to Aβ42-metabolism, microglial activity and synaptic/neuronal function) on atrophy rates in 7 AD-related regions. Besides effects of Aβ42 and phosphorylated tau (P-tau) that were seen in several regions, novel CSF proteins were found to have effects in inferior and middle temporal cortex (including Apolipoprotein CIII, Apolipoprotein D and Apolipoprotein H). Several proteins (including S100β and Matrix Metalloproteinase-3) had effects that depended on the presence of brain Aβ pathology, as measured by CSF Aβ42. Other proteins (including P-tau and Apolipoprotein D) had effects even after adjusting for CSF Aβ42. The statistical effects in this exploratory study were mild and not significant after correction for multiple comparisons, but some of the identified proteins may be associated with brain atrophy in healthy people. Proteins interacting with CSF Aβ42 may be related to Aβ brain pathology, while proteins associated with atrophy even after adjusting for CSF Aβ42 may be related to Aβ-independent mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 2×
“The tau pathology may also be present in the brain already at the third decade of life, although it is not known whether such deposits the constitute initial stages of AD (Braak et al., 2011).”
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 6×
“This is in agreement with previous studies of reduced CSF Ab42 and elevated CSF P-tau (Blennow et al., 2010) and ApoD (Craig-Schapiro et al.”
InfluentialSelf-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Rusinek, H., De Santi, S., Frid, D., Tsui, W.-H., Tarshish, C. Y., Convit, A., & de Leon, M. J. (2003) · Radiology · doi:10.1148/radiol.2293021299 · Cited by 281 · cited 1×
“An alternative is to study longitudinal atrophy of AD-related brain regions, which are predictive of future cognitive decline (Rusinek et al., 2003).”
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.016 · Cited by 106 · cited 4×
“A few studies have tested whether Ab pathology predicts longitudinal brain atrophy in cognitively healthy people (Chételat et al., 2012; Fjell et al., 2010; Henneman et al., 2009; Schott et al., 2010; Sluimer et al., 2010; Tosun et al., 2011).”
Influential
Cited by
Ayton, S., Faux, N. G., Bush, A. I., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms7760 · Cited by 327
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.007 · Cited by 315
Self-citationUnderstanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“A recent cerebrospinal fluid (CSF) biomarker study in cognitively healthy elderly suggests that increased CSF P-tau levels, possibly reflecting the presence of tangle pathology, are associated with atrophy in hippocampus and temporal lobe cortex independently of Ab pathology [47].”
BackgroundSelf-citationMatrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease
Wang, X.-X., Tan, M.-S., Yu, J.-T., & Tan, L. (2014) · BioMed Research International · doi:10.1155/2014/908636 · Cited by 55
Pentz, R., Iulita, M. F., Mikutra-Cencora, M., Ducatenzeiler, A., Bennett, D. A., & Cuello, A. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105150 · Cited by 31
Metadata
- Authors
- Mattsson, N., Insel, P., Nosheny, R., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Tosun, D., & Weiner, M.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 35
- Issue
- 3
- Pages
- 614-622
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2064661524
- Cited by
- 49
- References
- 10
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. https://app.cochat.ai/papers/10.1016/j.neurobiolaging.2013.08.027
- The paper
- Mattsson, N., Insel, P., Nosheny, R., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Tosun, D., & Weiner, M. (2014). Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging. https://doi.org/10.1016/j.neurobiolaging.2013.08.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.